AHA 2021 Heart Failure In-Depth

Dapagliflozin Has No Significant Effect on Cardiac Remodeling in T2D

By

Cardiology Advisor Contributing Writer

Researchers sought to determine whether dapagliflozin could help reverse left ventricular remodeling in patients with type 2 diabetes.

Tolvaptan Useful in Short-Term Dyspnea Relief During HF Hospitalization

By

Cardiology Advisor Contributing Writer

Researchers analyzed the effects of using tolvaptan as add-on therapy for patients hospitalized with acute heart failure.

Early Drop in Systolic BP Associated With All-Cause Mortality in Acute HF

By

Cardiology Advisor Contributing Writer

Through a subanalysis of the REALITY-AHF study, researchers were able to assess the negative effects of an early drop in systolic blood pressure in patients with acute heart failure.

Discharge on Sacubitril/Valsartan Shows Survival Benefit in HFrEF

By

Cardiology Advisor Contributing Writer

ARNI vs ACE inhibitors or ARB and outcomes in patients with HFrEF.

MRA Cessation Increases Mortality Risk in HF Patients With Hyperkalemia

By

Cardiology Advisor Contributing Writer

Study investigators analyzed the effects of MRA cessation on risk-benefit balance of patients with heart failure and hyperkalemia.

GLP-1 Receptor Agonists Linked to Lower Insulin Doses, HbA1c, Hospitalization in HF

By

Cardiology Advisor Contributing Writer

Researchers examined the outcomes of GLP-1 receptor agonist therapy in patients with heart failure.